Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

RARITAN, N.J., Oct. 11 /PRNewswire/ -- Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the ...

BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced additional data from the pivotal Phase 3 LATITUDE clinical trial, which showed that treatment with Zytiga ® ...

We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline ...

Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa). Primary analysis of ...

Please provide your email address to receive an email when new articles are posted on . Adding abiraterone acetate to androgen deprivation therapy plus docetaxel improved radiographic PFS and OS among ...

Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC): Subgroup analysis of LATITUDE ...

Phase I and Phase II Results Demonstrate Efficacy of CB7630 in Both Chemotherapy Naïve and Chemotherapy Refractory Castration Resistant Prostate Cancer Patients 2008 ASCO Annual Meeting LOS ...

Please provide your email address to receive an email when new articles are posted on . Two years of abiraterone acetate plus prednisolone-based therapy significantly improved survival among men with ...

LOUISVILLE, Ky--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson ...

Androgen receptor signaling remains important in castration-resistant prostate cancer (CRPC) as demonstrated by the efficacy of abiraterone acetate (henceforth abiraterone) in phase III trials. Given ...

Future Oncol. 2010;6(5):665-679. Given the efficacy and tolerability of abiraterone acetate, further studies of abiraterone acetate in combination with other chemotherapeutics and biologic agents are ...